Kim, Ji-Yeon
Lee, Eunjin
Park, Kyunghee
Im, Seock-Ah
Sohn, Joohyuk
Lee, Keun Seok
Chae, Yee Soo
Kim, Jee Hyun
Kim, Tae-Yong
Jung, Kyung Hae
Park, Yeon Hee http://orcid.org/0000-0003-4156-9212
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
https://doi.org/10.1007/s10549-019-05400-y
Funding for this research was provided by:
the National Research Foundation of Republic of Korea (NRF-2018R1A2B6004690)
the Ministry of Health and Welfare, Republic of Korea (HA17C0055)
the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1720150)
Article History
Received: 13 June 2019
Accepted: 6 August 2019
First Online: 12 August 2019
Compliance with ethical standards
:
: The authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards our institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.